(ADUS) Addus HomeCare - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 1.750m USD | Total Return: -19.4% in 12m
Avg Turnover: 25.6M
EPS Trend: 94.0%
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Addus HomeCare Corporation (ADUS) provides comprehensive home-based healthcare services across three primary segments: Personal Care, Hospice, and Home Health. The Personal Care division focuses on non-medical assistance with daily living activities, while the Hospice and Home Health segments provide skilled nursing, therapy, and palliative care for terminally ill or recovering patients. Founded in 1979 and headquartered in Frisco, Texas, the company serves a diverse payer base including governmental agencies, managed care organizations, and private insurers.
The home health sector is currently driven by a demographic shift as the aging U.S. population increasingly prefers aging in place over institutionalized care. This business model relies heavily on state and federal reimbursement rates, specifically through Medicaid and Medicare programs. For a deeper look into how these regulatory factors impact valuation, you can explore the data on ValueRay.
- Medicaid reimbursement rate increases drive organic revenue growth across core personal care segments
- Strategic acquisitions of regional hospice and home health providers accelerate market share expansion
- Labor cost inflation and caregiver shortages impact consolidated operating margins and service capacity
- Shifts in state-funded managed care programs influence long-term personal care contract stability
| Net Income: 99.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.17 > 1.0 |
| NWC/Revenue: 8.52% < 20% (prev 9.07%; Δ -0.55% < -1%) |
| CFO/TA 0.10 > 3% & CFO 144.9m > Net Income 99.8m |
| Net Debt (83.1m) to EBITDA (159.3m): 0.52 < 3 |
| Current Ratio: 1.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.5m) vs 12m ago 0.47% < -2% |
| Gross Margin: 32.45% > 18% (prev 0.33%; Δ 3.21k% > 0.5%) |
| Asset Turnover: 101.9% > 50% (prev 86.07%; Δ 15.81% > 0%) |
| Interest Coverage Ratio: 14.45 > 6 (EBITDA TTM 159.3m / Interest Expense TTM 9.88m) |
| A: 0.09 (Total Current Assets 272.9m - Total Current Liabilities 149.5m) / Total Assets 1.44b |
| B: 0.35 (Retained Earnings 497.4m / Total Assets 1.44b) |
| C: 0.10 (EBIT TTM 142.8m / Avg Total Assets 1.42b) |
| D: 1.56 (Book Value of Equity 497.4m / Total Liabilities 319.5m) |
| Altman-Z'' = 4.00 = AA |
| DSRI: 0.86 (Receivables 144.8m/141.5m, Revenue 1.45b/1.21b) |
| GMI: 1.00 (GM 32.45% / 32.56%) |
| AQI: 1.00 (AQ_t 0.76 / AQ_t-1 0.77) |
| SGI: 1.20 (Revenue 1.45b / 1.21b) |
| TATA: -0.03 (NI 99.8m - CFO 144.9m) / TA 1.44b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 93.18 with a total of 175,393 shares traded.
Over the past week, the price has changed by +0.58%,
over one month by -5.05%,
over three months by -10.42% and
over the past year by -19.42%.
Addus HomeCare has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy ADUS.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 132.7 | 42.4% |
P/E Trailing = 17.1095
P/E Forward = 13.3333
P/S = 1.2082
P/B = 1.5483
P/EG = 0.8894
Revenue TTM = 1.45b USD
EBIT TTM = 142.8m USD
EBITDA TTM = 159.3m USD
Long Term Debt = 91.3m USD (from longTermDebt, last quarter)
Short Term Debt = 13.1m USD (from shortTermDebt, last quarter)
Debt = 186.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 47.5m
Net Debt = 83.1m USD (calculated: Debt 186.2m - CCE 103.1m)
Enterprise Value = 1.83b USD (1.75b + Debt 186.2m - CCE 103.1m)
Interest Coverage Ratio = 14.45 (Ebit TTM 142.8m / Interest Expense TTM 9.88m)
EV/FCF = 13.34x (Enterprise Value 1.83b / FCF TTM 137.4m)
FCF Yield = 7.49% (FCF TTM 137.4m / Enterprise Value 1.83b)
FCF Margin = 9.48% (FCF TTM 137.4m / Revenue TTM 1.45b)
Net Margin = 6.89% (Net Income TTM 99.8m / Revenue TTM 1.45b)
Gross Margin = 32.45% ((Revenue TTM 1.45b - Cost of Revenue TTM 978.4m) / Revenue TTM)
Gross Margin QoQ = 31.87% (prev 33.13%)
Tobins Q-Ratio = 1.28 (Enterprise Value 1.83b / Total Assets 1.44b)
Interest Expense / Debt = 5.30% (Interest Expense 9.88m / Debt 186.2m)
Taxrate = 22.70% (7.36m / 32.4m)
NOPAT = 110.3m (EBIT 142.8m * (1 - 22.70%))
Current Ratio = 1.83 (Total Current Assets 272.9m / Total Current Liabilities 149.5m)
Debt / Equity = 0.17 (Debt 186.2m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = 0.52 (Net Debt 83.1m / EBITDA 159.3m)
Debt / FCF = 0.61 (Net Debt 83.1m / FCF TTM 137.4m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.02% (Net Income 99.8m / Total Assets 1.44b)
RoE = 9.34% (Net Income TTM 99.8m / Total Stockholder Equity 1.07b)
RoCE = 12.31% (EBIT 142.8m / Capital Employed (Equity 1.07b + L.T.Debt 91.3m))
RoIC = 8.88% (NOPAT 110.3m / Invested Capital 1.24b)
WACC = 7.05% (E(1.75b)/V(1.94b) * Re(7.36%) + D(186.2m)/V(1.94b) * Rd(5.30%) * (1-Tc(0.23)))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 5.73%
[DCF] Terminal Value 77.97% ; FCFF base≈118.5m ; Y1≈135.8m ; Y5≈199.9m
[DCF] Fair Price = 156.7 (EV 3.01b - Net Debt 83.1m = Equity 2.92b / Shares 18.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.00 | EPS CAGR: 12.68% | SUE: 0.40 | # QB: 0
Revenue Correlation: 98.47 | Revenue CAGR: 14.59% | SUE: -0.83 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.69 | Chg30d=+0.26% | Revisions=-14% | Analysts=14
EPS next Quarter (2026-09-30): EPS=1.76 | Chg30d=+0.41% | Revisions=+25% | Analysts=14
EPS current Year (2026-12-31): EPS=6.99 | Chg30d=+1.38% | Revisions=+65% | GrowthEPS=+12.2% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=7.47 | Chg30d=+0.40% | Revisions=+0% | GrowthEPS=+6.9% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +65%